Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors
This multicentre, prospective cohort study aims to enrol 375 patients with cirrhosis who meet the following criteria: 1. effective management or elimination of the primary aetiological factor (i.e., sustained virological response in chronic hepatitis C, complete viral suppression in chronic hepatitis B, or long-term alcohol abstinence in alcohol-related liver disease), 2. liver stiffness measurements under 25 kPa, and 3. absence of varices as confirmed by endoscopy Following the cessation of non-selective…
Conditions studied
Portal Hypertension, Cirrhosis, Varices, Esophageal
About this study
This multicentre, prospective cohort study aims to enrol 375 patients with cirrhosis who meet the following criteria: 1. effective management or elimination of the primary aetiological factor (i.e., sustained virological response in chronic hepatitis C, complete viral suppression in chronic hepatitis B, or long-term alcohol abstinence in alcohol-related liver disease), 2. liver stiffness measurements under 25 kPa, and 3. absence of varices as confirmed by endoscopy Following the cessation of non-selective beta-blockers, patients will undergo a follow-up endoscopy at the one-year mark. The study's primary endpoint is recurrent varices in 1 year. Success will be defined as the upper bound of the 95% confidence interval for recurrent varices being \<5%. Should this criterion be met, the study will extend to predefined analyses of variceal haemorrhage and hepatic decompensation at 3-and 10-year intervals (funded through local resources; the General Research Fund will cover patient recruitment costs for 1 year). Clinical assessments, laboratory tests, liver and spleen stiffness measurements will be performed at baseline, 3 months, 6 months and 12 months to identify potential predictors of variceal recurrence and assess the feasibility of early identification.
Primary outcomes
- Recurrent varices (1 year)
Eligibility information
Study locations
- Royal Prince Alfred Hospital, Sydney, Australia
- Southern Medical University, Guangzhou, China
- Ruijing Hospital, Shanghai, China
- Prince of Wales Hospital, Hong Kong, Hong Kong
- AIG Hospital, Hyderabad, India
- Institute of Liver and Biliary Sciences, New Delhi, India
- Changi General Hospital, Singapore, Singapore
- National University Hospital, Singapore, Singapore, Singapore
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.